Browse EX-10 agreements

1 1631165623.6 THE LOANS MAY HAVE BEEN ISSUED WITH “ORIGINAL ISSUE DISCOUNT” FOR U.S. FEDERAL INCOME TAX PURPOSES. [**] WILL MAKE AVAILABLE TO ANY LENDER: (1) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT OF THE LOAN, (2) THE ISSUE PRICE OF THE LOAN, (3) THE ISSUE DATE OF THE LOAN AND (4) THE YIELD TO MATURITY OF THE LOAN UPON RECEIVING A WRITTEN REQUEST FOR SUCH INFORMATION. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 4, 2026 and is entered into by and among LEXICON PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiary LEXICON PHARMACEUTICALS (NEW JERSEY), INC., a Delaware corporation (“Lexicon Sub”), its Subsidiary LION ACQUISITION CORPORATION, a Delaware corporation (“Lion”), each other Person that has delivered a Joinder Agreement pursuant to Section 7.13 from time to time party hereto (together with Company, Lexicon Sub, and Lion individually or collectively, as the context may require, “Borrower”), the several banks and other financial institutions or entities from time to time party hereto (each, a “Lender”, and colle

…

Execution Version

[CERTAIN INFORMATION, IDENTIFIED BY, AND REPLACED WITH, A MARK OF “[***]” HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.]

FORBEARANCE AGREEMENT

WHEREAS, this forbearance agreement (this “Agreement”), dated as of May 1, 2026 (“Effective Date”), is made by and among TerrAscend Corp., an Ontario corporation (“Parent”), TerrAscend USA, Inc., a Delaware corporation (“US Parent”), each other subsidiary of Parent signatory hereto (and, together with US Parent, collectively, the “Borrowers”, and each, individually, a “Borrower”; the Borrowers and Parent are collectively referred to as the “Loan Parties” and, each individually, a “Loan Party”), each lender party hereto (the “Lenders”), and FG Agency Lending LLC, as administrative agent (in such capacity, the “Agent”, and together with the Lenders, the “Secured Parties”). Parent, US Parent, the other Borrowers, the Lenders, and the Agent are referred to herein collectively as the “Parties” and each individually as a “

…

[CERTAIN INFORMATION, IDENTIFIED BY, AND REPLACED WITH, A MARK OF “[***]” HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.]

AMENDMENT NO. 5 TO LOAN AGREEMENT AND
AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT

This AMENDMENT NO. 5 TO LOAN AGREEMENT AND AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT, dated as of June 23, 2026 (this “Fifth Amendment”), is made by and among TerrAscend Corp., an Ontario corporation (“Parent”), as Guarantor, each Subsidiary of Parent identified on the signature pages hereto as “BORROWERS” (collectively, the “Borrowers”, and together with Parent, the “Loan Parties”), each of the Lenders party hereto, and FG Agency Lending LLC, as administrative agent for the Lenders (in such capacity, the “Agent”).

RECITALS:

…

SEPARATION AGREEMENT AND RELEASE

This Separation Agreement and Release (“Agreement”) is made by and between Theodora (Doretta) Mistras (“Executive”) and Viatris Inc. (together with its affiliates, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).

RECITALS

WHEREAS, Executive has voluntarily resigned as Chief Financial Officer of the Company, shall cease to serve in that position effective as of May 8, 2026 and shall separate from employment by the Company effective as of May 22, 2026 (the “Separation Date”); and

WHEREAS, the Company and Executive wish to set forth the terms of such separation from employment by the Company.

NOW, THEREFORE, in consideration of the mutual promises made herein and intending to be legally bound hereby, the Company and Executive hereby agree as follows:

COVENANTS

…

VIATRIS INC.
DIRECTOR DEFERRED STOCK UNIT
AWARD AGREEMENT

THIS DIRECTOR DEFERRED STOCK UNIT AWARD AGREEMENT(this “Agreement”), dated as of [_____] (the “Date of Grant”), is made by and between Viatris Inc., a Delaware corporation (the “Company”), and [_____](the “Participant”) in respect of Participant’s service as a member of the Board of Directors of the Company.

1.Grant of Deferred Stock Units.

(a)Grant. The Company hereby grants to the Participant a total of [_____] Deferred Stock Units (“DSUs”), on the terms and conditions set forth in this Agreement and as otherwise provided in the Viatris Inc. 2020 Stock Incentive Plan (as may be amended from time to time, the “Plan”) and the Viatris Inc. Non-Employee Director Deferral Election entered into by the Participant for the applicable calendar year and provided to the Company prior to the Grant Date (the “Deferral Election”). Each DSU represents the right to receive one share of the Company’s common stock, par value $0.01 per share (“Share”). The DSUs shall be credited to a separate book-entry account maintaine

…

VIATRIS INC.

NON-EMPLOYEE DIRECTOR DEFERRAL ELECTION

I.    Overview

If you would like to defer payment of your cash retainer or settlement of any restricted stock units (“RSUs”) that may be paid or granted to you by Viatris Inc. (the “Company”) in calendar year         , please complete and return this deferral form (the “Election Form”) to     , no later than      .

Permitted Deferral Dates. If you elect to defer receipt of your cash retainer, the cash amount otherwise payable to you will be deemed invested in Viatris shares in the form of deferred stock units (“DSUs”). If you elect to defer receipt of your RSUs, you will be electing to defer the settlement of the RSUs beyond their otherwise applicable vesting date.

You may elect to defer settlement of the DSUs and RSUs to the earliest of the following dates (such earliest date, the “Distribution Date”):

…

[Viatris Letterhead]

August 15, 2025

Andrew B. Enrietti

c/o last address on file with the Company

Dear Andrew:

On behalf of Viatris Inc. (the “Company”), I am pleased to confirm the terms of employment offered to you by the Company in connection with your promotion to the role of Chief Administrative and Transformation Officer effective as of August 15, 2025 (the “Effective Date”).

1.    Position. Your position shall be Chief Administrative and Transformation Officer, and you shall devote your full business time and attention to such position. You shall report to the Chief Executive Officer of the Company and you shall perform such duties as reasonably requested by the Chief Executive Officer.

2.    Work Location. Your principal work location shall be in Pittsburgh, Pennsylvania. You will also be required to travel as dictated by the business needs of the Company.

3.    Base Salary. Your annual base salary shall be $800,000 (“Base Salary”), payable on the Company’s standard payroll dates and subject to deductions and withholdings as required by applicable law.

…

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

EXECUTIVE EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of March 30, 2026 (the “Effective Date”), between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and

Dr. Richard Marshall (“Executive”).

RECITALS

A.Executive and the Company are entering into this Agreement setting forth the terms and conditions of Executive’s employment with the Company. The Company hereby employs Executive, and Executive hereby accepts employment with the Company, upon the terms and conditions contained in this Agreement.

B.As an executive employee of the Company, Executive will have access to and Executive will become familiar with, acquire knowledge of and develop or maintain the Confidential Information (as defined

…

SIGN-ON BONUS AGREEMENT

THIS SIGN-ON BONUS AGREEMENT (“Agreement”) is entered into on the 29th of June, 2026 (the “Effective Date”), by and between TriSalus Life Sciences, Inc., a Delaware

corporation (the “Company”), and Dr. Richard Marshall (the “Employee”).

NOW, THEREFORE, in consideration of the mutual promises made below, the parties agree as follows:

Sign-On Bonus. The Company agrees to pay Employee an annual sign-on bonus of $250,000 per year (the "Sign-On Bonus") for each year of the two-year initial term. The Year 1 Sign-On Bonus of $250,000 will be paid on the first payroll following the commencement of Executive's full-time employment on June 29, 2026. The Year 2 Sign-On Bonus of $250,000 will be paid on the first payroll following June 29, 2027. Each payment shall be subject to all applicable tax and other withholdings.

…

FIFTH AMENDMENT TO CREDIT AGREEMENT

This FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of May 28, 2026 by and among TRISALUS OPERATING LIFE SCIENCES, INC.,a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC.,a Delaware corporation (the “Parent”), the Lenders party hereto (the “Lenders”) and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the Lenders (in such capacity, and together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”).

…

A10 NETWORKS, INC. SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (the “Agreement”) is made by and between Sheen Khoury (“Executive”) and A10 Networks, Inc., a Delaware corporation (the “Company”) (collectively referred to as the “Parties”). WHEREAS, Executive is currently employed by the Company as Executive Vice President, Worldwide Sales & Marketing; WHEREAS, the employment relationship between Executive and the Company terminated effective April 27, 2026 (“Separation Date”) WHEREAS, Executive acknowledges that the Company has paid all earned wages, salary, bonuses, reimbursable expenses previously submitted by Executive and any similar payments due to Executive from the Company as of the Separation Date, and has provided Executive with any pertinent information attendant with the cessation of employment. Any group insurance coverage Executive received through the Company will remain in place through the end of the month of April, subject to continuation under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). Executive’s part

…

SOLID BIOSCIENCES INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”).

Director Compensation

Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company’s affairs. We also seek to align the interests of our directors and our stockholders, and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.

Cash Compensation

The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of each committee of the Board will be as follows:

…